Associate Director, Health Economics & Outcomes Research; HEOR

Who We Are

Bio Marin is a leading rare disease biotechnology company focused on genetically defined conditions.

Guided by our purpose to develop medicines that make a profound impact on people’s lives, our global teams have delivered a portfolio of therapies since our founding in 1997. Our revolutionary treatments for conditions like achondroplasia (the most common form of dwarfism), PKU (phenylketonuria), CLN2, a form of Batten disease, and a number of forms of MPS (mucopolysaccharidosis) offer new possibilities for patients and families who previously had few, if any, available options.

More recently, with the close of the Amicus acquisition, our portfolio has expanded to include therapies for Fabry disease and Pompe disease, expanding our ability to reach more people living with rare genetic conditions.

Our success comes from our unwavering commitment to excellence, our deep understanding of patient needs, our scientific expertise, and our world-class manufacturing capabilities. At the heart of Bio Marin is a dedicated team of the brightest minds in the industry working together to deliver innovative therapies to patients and families around the world.

Be part of the worldwide infrastructure that gets our drugs to underserved patients around the world. Our global sales force solidifies Bio Marin’s commercial presence in the United States and Europe and is rapidly growing in other regions, such as South America, EuMEA, and Asia-Pacific.

The Health Economics & Outcomes Research (HEOR) Associate Director supports asset‑specific payer evidence strategies, including patient‑relevant outcomes strategy, to generate differentiated evidence, strengthen the payer value proposition, and optimize access for Bio Marin assets across a specific therapeutic area of interest. This role contributes to shaping patient‑relevant outcomes requirements within the clinical programs, helping ensure alignment with Regulatory, HTA and access needs.

In partnership with internal cross‑functional and external stakeholders, the Associate Director supports the design and execution of patient‑relevant outcomes research initiatives.

The Associate Director builds effective working relationships with cross‑functional partners across Value & Access, Commercial, Medical Affairs, Clinical Development, Regulatory Affairs and Patient Advocacy, while supporting engagement with external stakeholders including HTA agencies, payers and patient organizations. This role requires solid expertise in patient‑relevant outcomes research and a strong understanding of market access, value and HTA frameworks.

The position reports to the Senior Director, HEOR within the Global HEOR team which sits within the Pricing Access Value & Evidence (PAVE) organization.

• Lead the development, execution and communication of payer evidence strategies aligned with brand and Value & Access priorities for early‑stage pipeline assets
• Collaborate closely with Value & Access, Commercial, Medical Affairs, Clinical Development & Regulatory Affairs & Patient Advocacy organizations
• Contribute to organizational understanding of payer and HTA requirements related to patient‑relevant outcomes and health utility measurement
• Support the strategic assessment of patient‑relevant outcomes requirements for HTA and access to support differentiation and value demonstration
• Ensure payer evidence requirements are incorporated into clinical development plans to enable optimal patient access
• Lead the development of cross‑functionally aligned, asset‑specific patient‑relevant outcomes strategies informed by disease conceptual models
• Support patient‑relevant endpoint planning and assist with implementation within clinical trials
• Lead early Joint Clinical Assessment (JCA) strategy development, including assessment of access implications and trade‑offs across markets
• Assess payer evidence gaps and inform future integrated evidence planning for early‑stage pipeline assets
• Manage and partner with external partners in the execution of asset‑level patient‑relevant outcomes strategies, including PRO development and validation, health state valuation studies (time…